Business Context and Reporting Period
Company: Trinity Biotech PLC
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: February 13, 2026
Reporting Period: February 2026
Context: The filing discloses a regulatory notice received from the Nasdaq Stock Market regarding listing compliance.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a listing compliance matter and does not contain financial performance data.
Material Changes
Nasdaq Non-Compliance Notice: On February 11, 2026, the Company received notice from Nasdaq that it is not in compliance with Listing Rule 5450(a)(1).
Reason: The Company's American depositary shares (ADSs) failed to maintain the minimum bid price of US $1.00 per share for the last 30 consecutive business days.
Compliance Period: The Company has been granted 180 calendar days, until August 10, 2026, to regain compliance.
Outlook, Risks, and Management Commentary
Risk: Failure to regain compliance with the minimum bid price requirement by August 10, 2026, could result in delisting from the Nasdaq Global Select Market.
Management Action: The Company has filed the press release regarding this notice as Exhibit 99.1. No specific remediation plan or financial guidance was detailed in this filing text.
Investor Verification Checklist
- Verify the current trading price of Trinity Biotech ADSs to assess the gap from the $1.00 threshold.
- Review the full text of the press release (Exhibit 99.1) for any announced share consolidation or other capital structure changes intended to address the bid price.
- Monitor future filings for updates on the Company's progress toward regaining compliance by the August 10, 2026 deadline.
- Check for any concurrent announcements regarding liquidity or financing that might impact the stock price.